Innate Pharma S.A.

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Shionogi Gets Daridorexant’s Japanese D

Rare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rare di

Arcus Biosciences is best known for its efforts to develop a TIGIT immunotherapy with Gilead, but the partners are also working on quemliclustat, a CD73 inhibitor, which has just produced promising P